Literature DB >> 8282432

Protective effects of silybin and tetrandrine on the outcome of spontaneously hypertensive rats subjected to acute coronary artery occlusion.

H Chen1, S C Chen, T H Zhang, H C Tian, Y Guan, D F Su.   

Abstract

The effects of silybin and tetrandrine on the survival of spontaneously hypertensive rats subjected to acute coronary artery occlusion were investigated. The mortality after acute coronary occlusion in spontaneously hypertensive rats (66.7%) was higher than that of control Wistar-Kyoto rats (20%, P < 0.05). Oral administration of silybin (300 mg/kg daily) for 8-12 days reduced mortality in spontaneously hypertensive rats (0, P < 0.01 in comparison with untreated spontaneously hypertensive rats). Administration of tetrandrine 40 mg/kg daily for 8-12 days reduced the mortality to some extent (22.2%, P = 0.051, as compared with control rats). Silybin reduced blood pressure and the incidence of post-occlusion arrhythmias in spontaneously hypertensive rats to the same extent as tetrandrine. Both silybin and tetrandrine decreased the severity of ventricular hypertrophy. Although there were significant decreases in risk zone and infarct zone in silybin- and tetrandrine-treated rats, the ratio of infarct to risk zone was not changed. The results implies that silybin may be beneficial when used in hypertensive patients who develop acute myocardial infarction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8282432     DOI: 10.1016/0167-5273(93)90148-a

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

Review 1.  A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block.

Authors:  Nikolaos P E Kadoglou; Chrystalla Panayiotou; Michail Vardas; Nikolaos Balaskas; Nikolaos G Kostomitsopoulos; Alexandra K Tsaroucha; Georgia Valsami
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

2.  Ketanserin improves cardiac performance after myocardial infarction in spontaneously hypertensive rats partially through restoration of baroreflex function.

Authors:  Jian-guang Yu; En-hui Zhang; Ai-jun Liu; Jian-guo Liu; Guo-jun Cai; Ding-feng Su
Journal:  Acta Pharmacol Sin       Date:  2013-11-18       Impact factor: 6.150

3.  Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent ERK1/2 signalling.

Authors:  Di-Fei Shen; Qi-Zhu Tang; Ling Yan; Yan Zhang; Li-Hua Zhu; Lang Wang; Chen Liu; Zhou-Yan Bian; Hongliang Li
Journal:  Br J Pharmacol       Date:  2010-01-25       Impact factor: 8.739

4.  The Effect of Silymarin Flavonolignans and Their Sulfated Conjugates on Platelet Aggregation and Blood Vessels Ex Vivo.

Authors:  Jana Pourová; Lenka Applová; Kateřina Macáková; Marie Vopršalová; Thomas Migkos; Roger Bentanachs; David Biedermann; Lucie Petrásková; Václav Tvrdý; Marcel Hrubša; Jana Karlíčková; Vladimír Křen; Kateřina Valentová; Přemysl Mladěnka
Journal:  Nutrients       Date:  2019-09-24       Impact factor: 5.717

Review 5.  The protective effects of silymarin on ischemia-reperfusion injuries: A mechanistic review.

Authors:  Vahid Akbari-Kordkheyli; Kazem Abbaszadeh-Goudarzi; Mohaddeseh Nejati-Laskokalayeh; Setareh Zarpou; Abbas Khonakdar-Tarsi
Journal:  Iran J Basic Med Sci       Date:  2019-09       Impact factor: 2.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.